4
Changes in Ownership
TEVA PHARMACEUTICAL INDUSTRIES LTD Filed Acc 0001209191-19-016085
Executive VP, Global R&D sold 409 shares at $16.88 ($6,905)
- Executive VP, Global R&D acquired 1,165 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Fridriksdottir Hafrun · Executive VP, Global R&D
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2019-03-04 | Exercise or conversion : show line 1 in the form | +1,165 | 16,502.51 | D | ||
| 2019-03-04 | Sale : show line 2 in the form | −409 | $16.88 | $6,905 | 16,093.51 | D |
| Open-market sales · 409 sh · avg $16.88 · $6,905 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2019-03-04 | Exercise or conversion : show line 3 in the form Restricted Share Units | −1,165 | 0 | D |
Loading xslF345X03/doc4.xml…